DDInter825 DDInter856
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
Glimepiride {u} (Compound) resembles {v} (Compound) Gliclazide
Glimepiride {u} (Compound) resembles {v} (Compound) Glisoxepide
Glimepiride {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
Glimepiride {u} (Compound) binds {v} (Gene) KCNJ11
Glimepiride {u} (Compound) is included by {v} (Pharmacologic Class) Sulfonylurea Compounds
Glimepiride {u} (Compound) causes {v} (Side Effect) Inappropriate antidiuretic hormone secretion
Glimepiride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methylcellulose
Glimepiride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lipoic acid
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chromium picolinate
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sermorelin
Glimepiride (Compound) resembles Gliclazide (Compound)
Glimepiride (Compound) resembles Glisoxepide (Compound)
Glimepiride (Compound) treats type 2 diabetes mellitus (Disease)
Glimepiride (Compound) binds KCNJ11 (Gene)
Glimepiride (Compound) is included by Sulfonylurea Compounds (Pharmacologic Class)
Glimepiride (Compound) causes Inappropriate antidiuretic hormone secretion (Side Effect)
Glimepiride may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Glimepiride may cause a minor interaction that can limit clinical effects when taken with Lipoic acid
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Sermorelin